NASDAQ:AKBA Akebia Therapeutics - AKBA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.56 0.00 (-0.50%) (As of 03/31/2023 05:27 PM ET) Add Compare Share Share Today's Range$0.54▼$0.5850-Day Range$0.56▼$1.1552-Week Range$0.24▼$2.56Volume1.07 million shsAverage Volume2.20 million shsMarket Capitalization$103.25 millionP/E RatioN/ADividend YieldN/APrice Target$1.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside124.3% Upside$1.25 Price TargetShort InterestHealthy3.63% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.67Based on 7 Articles This WeekInsider TradingSelling Shares$116,621 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.45) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector263rd out of 1,009 stocksPharmaceutical Preparations Industry116th out of 494 stocks 3.0 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.25, Akebia Therapeutics has a forecasted upside of 124.3% from its current price of $0.56.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.63% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 20.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 68.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.17. Previous Next 2.0 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Akebia Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 20 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,621.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 28.13% of the stock of Akebia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 11.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akebia Therapeutics (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.Read More Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Stock News HeadlinesMarch 31, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Trevena (TRVN), Akebia Therapeutics (AKBA) and Fennec Pharmaceuticals (FENC)March 30, 2023 | finance.yahoo.comAkebia Therapeutics Provides Update on Regulatory Process for VadadustatMarch 31, 2023 | WealthPop (Ad)Adam Mesh: “This Strategy Saved My Trading Career”Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. March 27, 2023 | bizjournals.comTwo struggling Mass. biotechs seek reverse stock splits to raise share pricesMarch 24, 2023 | finance.yahoo.comAkebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder MeetingMarch 13, 2023 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call TranscriptMarch 10, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Akebia Therapeutics (AKBA), Clearside Biomedical (CLSD) and Surface Oncology (SURF)March 10, 2023 | finance.yahoo.comQ4 2022 Akebia Therapeutics Inc Earnings CallMarch 31, 2023 | WealthPop (Ad)Adam Mesh: “This Strategy Saved My Trading Career”Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. March 9, 2023 | msn.comAkebia stock slumps ~20% amid 'cautious' outlook for Auryxia FY23 salesMarch 9, 2023 | finanznachrichten.deAkebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business HighlightsMarch 2, 2023 | finance.yahoo.comAkebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business HighlightsFebruary 24, 2023 | msn.comAkebia jumps 11% on EU nod to approve kidney disorder therapyFebruary 23, 2023 | finance.yahoo.comAkebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance DialysisFebruary 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Biohaven Ltd. (BHVN)February 21, 2023 | seekingalpha.comAkebia slips as FDA issues second response on appeal for kidney disease therapyFebruary 21, 2023 | finance.yahoo.comAkebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseaseFebruary 13, 2023 | reuters.comAKBA.OFebruary 13, 2023 | 247wallst.comUnusual Put Option Trade in Akebia Therapeutics Worth $304KFebruary 10, 2023 | nasdaq.comUnusual Put Option Trade in Akebia Therapeutics (AKBA) Worth $304.00KJanuary 5, 2023 | thestreet.comAkebia Therapeutics (AKBA) Stock Declines Following Pricing of Secondary OfferingDecember 22, 2022 | markets.businessinsider.comAkebia Receives Interim Response From FDA To Appeal For VadadustatDecember 22, 2022 | finance.yahoo.comAkebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDANovember 22, 2022 | finance.yahoo.comAkebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comAkebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 4, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Akebia Therapeutics (AKBA)November 3, 2022 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Company Calendar Last Earnings11/04/2021Today3/31/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees426Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.25 High Stock Price Forecast$1.25 Low Stock Price Forecast$1.25 Forecasted Upside/Downside+212.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,560,000.00 Net Margins-31.63% Pretax Margin-31.63% Return on Equity-279.65% Return on Assets-16.92% Debt Debt-to-Equity Ratio3.65 Current Ratio1.48 Quick Ratio1.31 Sales & Book Value Annual Sales$292.60 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book11.20Miscellaneous Outstanding Shares184,250,000Free Float177,468,000Market Cap$103.16 million OptionableOptionable Beta0.84 Key ExecutivesJohn P. ButlerPresident, Chief Executive Officer & DirectorMichel DahanChief Operating Officer & Senior Vice PresidentDavid A. SpellmanTreasurer, Chief Financial & Accounting OfficerSteven K. BurkeChief Medical Officer & SVP-Research & DevelopmentMichael RabinowitzVice President-ResearchKey CompetitorsParatek PharmaceuticalsNASDAQ:PRTKBriaCell TherapeuticsNASDAQ:BCTXTiziana Life SciencesNASDAQ:TLSAViveon Health AcquisitionNYSE:VHAQAffimedNASDAQ:AFMDView All CompetitorsInsiders & InstitutionsJohn P ButlerSold 91,868 sharesTotal: $80,843.84 ($0.88/share)David A SpellmanSold 7,210 sharesTotal: $6,344.80 ($0.88/share)Nicole R HadasSold 13,034 sharesTotal: $11,469.92 ($0.88/share)Michel DahanSold 20,412 sharesTotal: $17,962.56 ($0.88/share)Alerce Investment Management L.P.Bought 10,437,558 shares on 2/15/2023Ownership: 8.203%View All Insider TransactionsView All Institutional Transactions AKBA Stock - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AKBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price forecast for 2023? 2 brokerages have issued 12 month target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $1.25 to $1.25. On average, they predict the company's share price to reach $1.25 in the next year. This suggests a possible upside of 121.9% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2023? Akebia Therapeutics' stock was trading at $0.5770 on January 1st, 2023. Since then, AKBA stock has decreased by 2.4% and is now trading at $0.5632. View the best growth stocks for 2023 here. Are investors shorting Akebia Therapeutics? Akebia Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 6,680,000 shares, a decline of 20.3% from the February 28th total of 8,380,000 shares. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is presently 3.0 days. View Akebia Therapeutics' Short Interest. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.02. The biopharmaceutical company had revenue of $48.76 million for the quarter, compared to the consensus estimate of $50.09 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 279.65% and a negative net margin of 31.63%. During the same quarter in the prior year, the company earned ($0.42) EPS. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alerce Investment Management L.P. (8.20%), Renaissance Technologies LLC (1.57%), Geode Capital Management LLC (0.91%), Millennium Management LLC (0.73%), Two Sigma Investments LP (0.20%) and Public Employees Retirement System of Ohio (0.08%). Insiders that own company stock include David A Spellman, Dell Faulkingham, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $0.56. How much money does Akebia Therapeutics make? Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $103.77 million and generates $292.60 million in revenue each year. The biopharmaceutical company earns $-92,560,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. How many employees does Akebia Therapeutics have? The company employs 426 workers across the globe. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099. This page (NASDAQ:AKBA) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.